

Supplementary Table 4. Multivariate Cox-regression model for progression-free survival (PFS) for patients with pancreatic neuroendocrine neoplasms (PanNENs) receiving first line molecular targeted therapy (MTT).

Prognostic factor for PFS	HR	95%CI	P-value
MTT agent			
Everolimus	1		
Sunitinib	4.9	1.8-13.9	0.002
Age at baseline	0.98	0.95-1.01	0.247
Grade			
G1 (Ki67<3%)	1		
G2 (Ki67 3-20%)	0.693	0.4-4	0.693
G3 (Ki67 >20%)	76.3	5-1171	0.002
SRS or Ga68-PET			
Negative	1		
Positive	1.6	0.42-6.1	0.494
Unknown	0.3	0.04-2.35	0.252
Prior Resective Surgery			
No	1		
Yes	0.8	0.35-1.8	0.585
Prior Chemotherapy			
No	1		
Yes	1.79	0.68-4.7	0.242

HR: hazard ratio, CI: confidence interval, G: grade; SRS: somatostatin receptor scintigraphy; Ga: gallium